OBJECTIVE: The somatotropic axis (growth hormone [GH] and insulinlike growth factor I [IGFI]) play a role in the cognitive deficits seen with aging, GH deficiency, and neurodegenerative disorders such as Alzheimer disease. We recently reported elevations in basal plasma GH and IGFI levels in patients with Huntington disease (HD). Here, our objective was to determine whether somatotropic axis abnormalities predicted cognitive dysfunction in HD. METHODS: In this prospective cohort study of 109 patients with genetically documented HD, aged 21 to 85 years, we determined fasting blood levels of total IGFI, GH, and insulinlike factor binding protein 3 at baseline, and we used the cognitive Unified Huntington's Disease Rating Scale to assess cognitive impairment at baseline and for up to 5 years subsequently. Associations were evaluated using mixed linear model analysis. RESULTS: Higher plasma IGFI concentrations were associated with greater cognitive decline (beta Stroop Words, -6.01, p = 0.003; beta Stroop Color, -4.41, p = 0.01; beta Stroop Color/Words, -3.86, p = 0.02; beta Symbol Digit Modalities, -3.69, p = 0.03; and beta verbal fluency, -5.01, p = 0.03). Higher free IGFI concentrations and higher GH concentrations in men also predicted greater cognitive decline. CONCLUSIONS: Our findings in patients with HD suggest that a high IGFI level at baseline may be associated with greater subsequent declines in executive function and attention.
OBJECTIVE: The somatotropic axis (growth hormone [GH] and insulinlike growth factor I [IGFI]) play a role in the cognitive deficits seen with aging, GH deficiency, and neurodegenerative disorders such as Alzheimer disease. We recently reported elevations in basal plasma GH and IGFI levels in patients with Huntington disease (HD). Here, our objective was to determine whether somatotropic axis abnormalities predicted cognitive dysfunction in HD. METHODS: In this prospective cohort study of 109 patients with genetically documented HD, aged 21 to 85 years, we determined fasting blood levels of total IGFI, GH, and insulinlike factor binding protein 3 at baseline, and we used the cognitive Unified Huntington's Disease Rating Scale to assess cognitive impairment at baseline and for up to 5 years subsequently. Associations were evaluated using mixed linear model analysis. RESULTS: Higher plasma IGFI concentrations were associated with greater cognitive decline (beta Stroop Words, -6.01, p = 0.003; beta Stroop Color, -4.41, p = 0.01; beta Stroop Color/Words, -3.86, p = 0.02; beta Symbol Digit Modalities, -3.69, p = 0.03; and beta verbal fluency, -5.01, p = 0.03). Higher free IGFI concentrations and higher GH concentrations in men also predicted greater cognitive decline. CONCLUSIONS: Our findings in patients with HD suggest that a high IGFI level at baseline may be associated with greater subsequent declines in executive function and attention.
Authors: Luana Naia; I Luísa Ferreira; Teresa Cunha-Oliveira; Ana I Duarte; Márcio Ribeiro; Tatiana R Rosenstock; Mário N Laço; Maria J Ribeiro; Catarina R Oliveira; Frédéric Saudou; Sandrine Humbert; A Cristina Rego Journal: Mol Neurobiol Date: 2014-05-20 Impact factor: 5.590
Authors: Sara J Tallaksen-Greene; Marianna Sadagurski; Li Zeng; Roseanne Mauch; Matthew Perkins; Varuna C Banduseela; Andrew P Lieberman; Richard A Miller; Henry L Paulson; Roger L Albin Journal: J Neurosci Date: 2014-11-19 Impact factor: 6.167
Authors: Nimra Hasnain; Taha Bin Arif; Roha Shafaut; Faiza Zakaria; Syeda Zainab Fatima; Ibtehaj Ul Haque Journal: Wien Med Wochenschr Date: 2022-06-20
Authors: Paula García-Huerta; Paulina Troncoso-Escudero; Di Wu; Arun Thiruvalluvan; Marisol Cisternas-Olmedo; Daniel R Henríquez; Lars Plate; Pedro Chana-Cuevas; Cristian Saquel; Peter Thielen; Kenneth A Longo; Brad J Geddes; Gerardo Z Lederkremer; Neeraj Sharma; Marina Shenkman; Swati Naphade; S Pablo Sardi; Carlos Spichiger; Hans G Richter; Felipe A Court; Kizito Tshitoko Tshilenge; Lisa M Ellerby; R Luke Wiseman; Christian Gonzalez-Billault; Steven Bergink; Rene L Vidal; Claudio Hetz Journal: Acta Neuropathol Date: 2020-07-08 Impact factor: 17.088
Authors: Julie C Stout; Rebecca Jones; Izelle Labuschagne; Alison M O'Regan; Miranda J Say; Eve M Dumas; Sarah Queller; Damian Justo; Rachelle Dar Santos; Allison Coleman; Ellen P Hart; Alexandra Dürr; Blair R Leavitt; Raymund A Roos; Doug R Langbehn; Sarah J Tabrizi; Chris Frost Journal: J Neurol Neurosurg Psychiatry Date: 2012-05-07 Impact factor: 10.154